NanoSanguis S.A., a biotechnology company belonging to the NanoGroup, has been selected for funding in the amount of PLN 22,760,796.26. The funds come from the European Funds for a Modern Economy (FENG) 2021-2027 program and will be used for the development of NanOX 4 Kidney. The awarded support is equivalent to about 20% of NanoGroup S.A.’s current stock market capitalization. It represents an important validation of the project and the potential of the technology under development.

NanOX 4 Kidney is a next-generation kidney perfusion fluid based on a synthetic oxygen carrier. The goal of the project is to improve the quality of stored organs for transplantation and extend the time for their safe transport.

The awarding of a grant under FENG, one of the most important programs supporting innovation in Poland, strengthens NanoSanguis’ position as an entity developing breakthrough technologies in the field of transplantation. It also sends a positive signal to current and potential investors, confirming the investment potential of the project and the NanoGroup as a whole.
At the same time, NanoSanguis S.A. also signed an executive agreement with A4BEE Sp. z o.o. (worth over PLN 2.3 million). A4BEE undertook to manufacture 3 copies of the NanOX Recovery Box in a version compliant with current CE standards, together with technical documentation and software. Execution of the contract will allow subsequent application for certification of the device.